Fig. 4: MeCP2 binding to chromatin is regulated by the levels of H3K27me3.

a SH-SY5Y cells treated with either DMSO or GSK343 were immunoprecipitated with either histone H3 or MeCP2 antibody. Samples of input were analyzed with Western blot for MeCP2, histone H3 and H3K27me3. IgG and immunoprecipitates were analyzed with Western blot for MeCP2 and histone H3. Star indicates a non-specific band. Source data are provided as a Source Data file. b Scatter plots show the correlation between H3K27me3 ChIP-seq signal and MeCP2 enrichment from SH-SY5Y cells (binning size =  1000 bp). N = 2 (WT) from biologically independent experiments. c Differences of exogenous reference normalized H3K27me3-enrichment between GSK343 treatment and control DMSO are plotted. N = 2 (per treatment) from biologically independent experiments. The x axis corresponds to the average of H3K27me3 signals in both GSK343 treated and DMSO control; the y axis corresponds to the difference of H3K27me3 signal between GSK343 treated and DMSO control SH-SY5Y cells. Based on the H3K27me3 difference, loci are categorized as unchanged (gray), moderate (green) or severe (purple). d MeCP2 enrichment of DMSO or GSK343-treated samples, separated by groups defined in c. N = 2 (per treatment, DMSO vs GSK343) from biologically independent experiments. n = 333,212, p < 0.0001 (Unchanged, gray); n = 16,434, p < 0.0001 (Moderate, green); n = 691, p = 7.75 × 10⁻⁵¹ (Severe, purple) (two-tailed Wilcoxon signed-rank test, *** p < 0.0001). p = 0.00 were reported as p < 0.0001. Box-and-whisker plots show median, 10–90 percentile, and min and max values.